Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 21 小时前评分45
正文 · 机器翻译
PACE-LUNG #ESMO26
ctDNA 指导下的治疗强化：EGFR 突变型 NSCLC 中，以早期分子应答指导适应性治疗 🫁
#LungCancer @OncoAlert #LCSM
257 浏览 · 11 赞 · 5 转发 · 0 回复
会议摘要
2700RO按 Rapid oral 1: NSCLC, metastatic 对上
Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort
https://esmocongress.esmo.orgExtended circulating tumor DNA (ctDNA) sequencing to optimize the selection between anti-EGFR rechallenge and other later lines in patients with RAS/BRAF wild-type metastatic colorectal cancer
https://esmocongress.esmo.orgNCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org来源：Aya Mohamed | MSc, MD 🎗 · x.com